TY - JOUR
T1 - An engineered tumor organoid model reveals cellular identity and signaling trajectories underlying translocation RCC
AU - Ganpat, Maroussia
AU - Pham, Nhung
AU - Lijnzaad, Philip
AU - Morales-Rodriguez, Francisco
AU - de Souza, Terezinha
AU - Derakhshan, Sepideh
AU - Fumagalli, Arianna
AU - Zeller, Peter
AU - Balwierz, Aleksandra
AU - Ayyildiz, Dilara
AU - van den Heuvel - Eibrink, Marry
AU - de Krijger, Ronald
AU - van Oudenaarden, Alexander
AU - Margaritis, Thanasis
AU - Chuva de Sousa Lopes, Susana M.
AU - Drost, Jarno
PY - 2023
Y1 - 2023
N2 - Translocation renal cell carcinoma (tRCC) is a rare, aggressive type of kidney cancer primarily occurring in children. They are genetically defined by translocations involving MiT/TFE gene family members, TFE3 or, in rare cases, TFEB. The biology underlying tRCC development remains poorly understood, partly due to the lack of representative experimental models. Here, we utilized human kidney organoids, or tubuloids, to engineer a tRCC model by expression of one of the most common MiT/TFE fusions, SFPQ-TFE3. Fusion expressing tubuloids adopt a tRCC-like phenotype and gene expression signature in vitro and grow as clear cell RCC upon xenotransplantation in mice. Genome-wide binding analysis reveals that SFPQ-TFE3 reprograms gene expression signatures by aberrant, gain-of-function genome-wide DNA binding. Combining these analyses with single-cell mRNA readouts reveals an epithelium-to-mesenchymal differentiation trajectory underlying tRCC transformation, potentially caused by deregulated Wnt signaling. Our study demonstrates that SFPQ-TFE3 expression is sufficient to transform kidney epithelial cells into tRCC and defines the trajectories underlying malignant transformation, thereby facilitating the development of new therapeutic interventions.
AB - Translocation renal cell carcinoma (tRCC) is a rare, aggressive type of kidney cancer primarily occurring in children. They are genetically defined by translocations involving MiT/TFE gene family members, TFE3 or, in rare cases, TFEB. The biology underlying tRCC development remains poorly understood, partly due to the lack of representative experimental models. Here, we utilized human kidney organoids, or tubuloids, to engineer a tRCC model by expression of one of the most common MiT/TFE fusions, SFPQ-TFE3. Fusion expressing tubuloids adopt a tRCC-like phenotype and gene expression signature in vitro and grow as clear cell RCC upon xenotransplantation in mice. Genome-wide binding analysis reveals that SFPQ-TFE3 reprograms gene expression signatures by aberrant, gain-of-function genome-wide DNA binding. Combining these analyses with single-cell mRNA readouts reveals an epithelium-to-mesenchymal differentiation trajectory underlying tRCC transformation, potentially caused by deregulated Wnt signaling. Our study demonstrates that SFPQ-TFE3 expression is sufficient to transform kidney epithelial cells into tRCC and defines the trajectories underlying malignant transformation, thereby facilitating the development of new therapeutic interventions.
U2 - 10.1101/2023.09.01.554626
DO - 10.1101/2023.09.01.554626
M3 - Article
JO - bioRxiv
JF - bioRxiv
ER -